Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/eci.13429

http://scihub22266oqcxt.onion/10.1111/eci.13429
suck pdf from google scholar
33058143!7646004!33058143
unlimited free pdf from europmc33058143    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33058143      Eur+J+Clin+Invest 2021 ; 51 (1): e13429
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis #MMPMID33058143
  • Mulchandani R; Lyngdoh T; Kakkar AK
  • Eur J Clin Invest 2021[Jan]; 51 (1): e13429 PMID33058143show ga
  • INTRODUCTION: The coronavirus pandemic has affected more than 20 million people so far. Elevated cytokines and suppressed immune responses have been hypothesized to set off a cytokine storm, contributing to ARDS, multiple-organ failure and, in the most severe cases, death. We aimed to quantify the differences in the circulating levels of major inflammatory and immunological markers between severe and nonsevere COVID-19 patients. METHODS: Relevant studies were identified from PubMed, EMBASE, Web of Science, SCOPUS and preprint servers. Risk of bias was assessed for each study, using appropriate checklists. All studies were described qualitatively and a subset was included in the meta-analysis, using forest plots. RESULTS: Based on 23 studies, mean cytokine levels were significantly higher (IL-6: MD, 19.55 pg/mL; CI, 14.80, 24.30; IL-8: MD, 19.18 pg/mL; CI, 2.94, 35.43; IL-10: MD, 3.66 pg/mL; CI, 2.41, 4.92; IL-2R: MD, 521.36 U/mL; CI, 87.15, 955.57; and TNF-alpha: MD, 1.11 pg/mL; CI, 0.07, 2.15) and T-lymphocyte levels were significantly lower (CD4+ T cells: MD, -165.28 cells/microL; CI, -207.58, -122.97; CD8+ T cells: MD, -106.51 cells/microL; CI, -128.59, -84.43) among severe cases as compared to nonsevere ones. There was heterogeneity across studies due to small sample sizes and nonuniformity in outcome assessment and varied definitions of disease severity. The overall quality of studies was sub-optimal. CONCLUSION: Severe COVID-19 is characterized by significantly increased levels of pro-inflammatory cytokines and reduced T lymphocytes. Well-designed and adequately powered prospective studies are needed to amplify the current evidence and provide definitive answers to dilemmas regarding timing and type of anti-COVID-19 therapy particularly in severe patients.
  • |CD4 Lymphocyte Count[MESH]
  • |CD4-Positive T-Lymphocytes/*immunology[MESH]
  • |CD8-Positive T-Lymphocytes/*immunology[MESH]
  • |COVID-19/blood/*immunology[MESH]
  • |Cytokine Release Syndrome/*immunology[MESH]
  • |Cytokines/*immunology[MESH]
  • |Humans[MESH]
  • |Interleukin-10/immunology[MESH]
  • |Interleukin-6/immunology[MESH]
  • |Interleukin-8/immunology[MESH]
  • |Lymphocyte Count[MESH]
  • |Receptors, Interleukin-2/immunology[MESH]
  • |SARS-CoV-2[MESH]
  • |Severity of Illness Index[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box